Ginkgo Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials
• Forums

Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome
Conditions:   Motoric Cognitive Risk Syndrome;   Mild Cognitive Impairment;   Aging;   Locomotive Syndrome Interventions:   Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution;   Drug: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution Sponsors:   Beijing Tiantan Hospital;   Beijing Stroke Association Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 30, 2020 Category: Research Source Type: clinical trials